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Cost-effectiveness of 
cardiac rehabilitation 
in ESRD patients
It is well known that patients with end-
stage renal disease (ESRD) have a higher 
incidence of cardiovascular complications. 
Following any cardiac bypass surgery, it is 
standard to prescribe cardiac rehabilita-
tion. But what is the cost of this interven-
tion, and is it necessary in ESRD patients? 
In this issue, Huang et al. present a study 
of  more than 4000 ESRD patients who 
had undergone a coronary artery bypass 
grafting procedure. During a 42-month 
follow-up period, cardiac rehabilitation 
was associated with higher cumulative 
Medicare expenditures, but this additional 
cost was not statistically significant. Dur-
ing the same period, cardiac rehabilitation 
was significantly associated with longer 
cumulative life, having an incremental 
benefit of 76 days. Thus, cardiac rehabilita-
tion was found to be highly cost-effective 
in patients with ESRD. See page 1079.
Oral vitamin D 
improves survival  
in ESRD patients  
on dialysis
Injectable calcitriol, or vitamin D, is 
clearly associated with a survival benefit, 
but the effect of the oral form—widely 
used in many countries for the treatment 
of secondary hyperparathyroidism in 
ESRD—remains to be tested. Naves-Díaz 
et al. examined its role in the survival of 
ESRD patients on dialysis from six Latin 
American countries. After 16 months of 
treatment, the 7203 patients who received 
oral active vitamin D had significant 
reductions in overall, cardiovascular, 
infectious, and neoplastic mortality com-
pared with the 8801 patients who had not 
received vitamin D. The survival benefit 
of oral active vitamin D was seen in those 
patients receiving mean daily doses of 
less than 1 µg; the highest reduction was 
associated with the lowest dose. This study 
shows that oral vitamin D is effective in 
improving survival among patients with 
ESRD. See page 1070.
Carbon monoxide as 
an ex vivo preservative 
during cold ischemia
Carbon monoxide is now well known to 
be an important ‘hormone’ in that it is 
produced by normal cells and has effects 
that are mostly local in nature. Unlike its 
role as a poison in ordinary life, its role in 
physiology is largely protective. In a new 
study, Nakao et al. tested its effectiveness 
in combating renal ischemia/reperfusion 
injury after kidney transplantation, an 
especially common problem. They used 
orthotopic syngeneic kidney transplan-
tation in Lewis rats following 24 hours 
of cold preservation in solution media 
equilibrated with or without carbon 
monoxide. Control rats showed an early 
elevation of inflammatory cytokines and 
progressive deterioration of graft func-
tion. However, the grafts perfused with 
carbon monoxide had significantly less 
oxidative injury and improved recipient 
survival compared with the control group. 
In the control group, cytochrome P450 
heme proteins were degraded, metabo-
lism of heme occurred, and intracellular 
free heme levels increased. On the other 
hand, kidney grafts perfused with carbon 
monoxide–equilibrated media maintained 
their cytochrome P450 protein levels, had 
normal intracellular heme levels, and had 
less lipid peroxidation. These studies dem-
onstrate that carbon monoxide may have 
an important role in the preservation of 
kidney grafts before transplantation. 
See page 1009.
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